Cimzia is a prescription-only biologic medication that is intended to manage inflammatory diseases i.e. rheumatoid arthritis, axial spondylarthrosis, and psoriatic arthritis. This medication is a product of UCB Pharma, a scientific research company headquartered in Brussels, Belgium. The active ingredient— 200mg of certolizumab pegol—is a PEGylated tumor necrosis factor (TNF) blocker. Tumor necrosis factor (TNF) is a pro-inflammatory cytokine that is released by the body during inflammation. Though its normal mechanism of action is to help regulate the inflammation process, patients with inflammatory disorders have elevated levels of TNF in their system, resulting in symptoms like pain and stiffness of the joints. Cimzia is then formulated to help bind and neutralize both free and membrane-bound human TNF, so as to reduce the severity of the inflammation. This medicine is supplied as a colorless to yellow injectable solution that must be administered via subcutaneous injection. Each box of this prescription-only medicine comes with 2-1ml ready-to-use syringes prefilled with the solution for injection. Store this drug in the refrigerator with the temperature is between 2°C to 25°C. Keep it protected from direct sunlight and freezing conditions.